title: Episcleral implants for topotecan delivery to the posterior segment of the eye.
abstract: Purpose. Intravenous or periocular topotecan has been proposed as new treatment modality for patients with advanced intraocular retinoblastoma, but systemic topotecan lactone exposure induced by both approaches may cause toxicity. The purpose of this study was to develop a topotecan-loaded ocular delivery system to minimize systemic exposure and achieve selective transscleral penetration. Methods. Biocompatible polymer implants containing low (0.3 mg) or high (2.3 mg) topotecan load were manufactured and characterized in vitro. Adrenaline (500 mug) was coloaded to induce local vasoconstriction in vivo in 2 of 4 animal groups. Implants were inserted into the episclera of rabbits, and topotecan (lactone and total) concentrations in ocular tissues and plasma were determined over a period of 48 hours. Results. In vitro, implants released 30% to 50% of the loaded drug within 48 hours and 45% to 70% by day 10. In vivo, topotecan lactone was highly accumulated in locally exposed ocular tissues (ranging from 10(5) to 10(6) ng/g in sclera and choroid and 10(2) to10(3) ng/g in retina) over 48 hours with all the formulations studied. Low vitreous topotecan lactone levels (approximately 5 ng/mL) were found in animals receiving concomitant local vasoconstriction and high load implants. Topotecan lactone concentrations in plasma and in contralateral eyes were minimal or undetectable as a marker of tissue selectivity of the proposed strategy. Conclusions. These studies may contribute to improving the efficacy and safety of chemotherapy treatments for retinoblastoma and may support the role of the local vasculature and tissues promoting drug clearance and local accumulation during transscleral drug delivery.
authors.affiliation: Department of Pharmacology, University of Buenos Aires, Buenos Aires, Argentina.
authors.forename: Angel M
authors.initials: AM
authors.lastname: Carcaboso
authors.forename: Diego A
authors.initials: DA
authors.lastname: Chiappetta
authors.forename: Javier A W
authors.initials: JA
authors.lastname: Opezzo
authors.forename: Christian
authors.initials: C
authors.lastname: Höcht
authors.forename: Adriana C
authors.initials: AC
authors.lastname: Fandiño
authors.forename: J Oscar
authors.initials: JO
authors.lastname: Croxatto
authors.forename: Modesto C
authors.initials: MC
authors.lastname: Rubio
authors.forename: Alejandro
authors.initials: A
authors.lastname: Sosnik
authors.forename: David H
authors.initials: DH
authors.lastname: Abramson
authors.forename: Guillermo F
authors.initials: GF
authors.lastname: Bramuglia
authors.forename: Guillermo L
authors.initials: GL
authors.lastname: Chantada
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002829:Choroid / Q000187:drug effects* / Q000378:metabolism; D016503:Drug Delivery Systems; D004343:Drug Implants; D004837:Epinephrine / Q000008:administration & dosage; D011091:Polyesters; D011817:Rabbits; D012160:Retina / Q000187:drug effects* / Q000378:metabolism; D012590:Sclera; D014018:Tissue Distribution; D019772:Topotecan / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000970:Antineoplastic Agents; D004343:Drug Implants; D011091:Polyesters; C016240:polycaprolactone; D019772:Topotecan; D004837:Epinephrine